Valuation: Waverley Pharma Inc.

Market Cap 1.35M 951K 832K 768K 716K 89.88M 1.37M 9.21M 3.58M 44.35M 3.57M 3.49M 155M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.75M 3.34M 2.93M 2.7M 2.52M 316M 4.83M 32.41M 12.58M 156M 12.57M 12.28M 544M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 month+150.00%
3 months+66.67%
6 months+25.00%
Current year+25.00%
1 month 0.02
Extreme 0.015
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.14
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member - 22/11/2023
Date Insider Type Main position Quantity % Market Cap.
24/06/24Other

Director

0 0%
18/08/21Option

Chairman

10,000,000 18.5185%
18/08/21Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+150.00%-37.50% 950K
+3.31%-0.20%+72.71%+128.31% 55.78B
-1.32%+17.12%+79.02%+99.82% 55.66B
-1.28%+2.68%-12.60%-13.79% 23.84B
+1.79%+4.38%+5.94%+405.31% 22.7B
-1.93%+11.11%+34.89%-7.86% 18.5B
+4.45%+5.06%+36.50%-30.43% 16.12B
+0.24%+5.98%+23.45%+184.72% 13.64B
+0.14%+9.60%+33.31% - 12.95B
+1.83%+4.58%+77.42%+132.45% 12.16B
Average +0.72%+5.49%+50.06%+95.67% 23.14B
Weighted average by Cap. +0.80%+5.21%+48.48%+114.84%

Financials

2024 2025
Net sales 475K 335K 293K 270K 252K 31.65M 484K 3.24M 1.26M 15.62M 1.26M 1.23M 54.41M 1.35M 950K 832K 768K 716K 89.86M 1.37M 9.21M 3.58M 44.34M 3.57M 3.49M 154M
Net income -947K -667K -584K -539K -503K -63.06M -964K -6.46M -2.51M -31.12M -2.51M -2.45M -108M -499K -352K -308K -284K -265K -33.24M -508K -3.41M -1.32M -16.4M -1.32M -1.29M -57.14M
Net Debt 2.83M 1.99M 1.74M 1.61M 1.5M 188M 2.88M 19.32M 7.5M 93M 7.49M 7.32M 324M 3.4M 2.39M 2.1M 1.93M 1.8M 226M 3.46M 23.2M 9.01M 112M 8.99M 8.79M 389M
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
23/06/26 CA$0.0250 -.--% 1,730
  1. Stock Market
  2. Stocks
  3. WAVE Stock